Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
SCHAUMBURG, Ill., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 13, 2016 at 2:00 p.m. PT (4:00 p.m. CT/5:00 p.m. ET). The presentation is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website, www.sagentpharma.com. In order to register and download any necessary software, please log on 10 minutes prior to the start of the webcast.
A replay of the webcast will be available until Tuesday, February 16, 2016 and can be accessed on the Sagent website.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a global specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.
INVESTOR CONTACT: Jonathon Singer, Sagent [email protected] 847-908-1605
